跳至主要内容
临床试验/NL-OMON51993
NL-OMON51993尚未招募2 期

A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD) - Deferiprone as possible treatment for Pelizaeus-Merzbacher disease

Vrije Universiteit Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 11(—)

入选标准

  • - Genetically proven PMD with a clinically relevant mutation in PLP1 (missense
  • mutation or duplication/triplication) and an MRI compatible with the diagnosis.
  • - Present age between 6 months and 8 years of age.
  • - Connatal or classic form of the disease (defined as not being able to sit
  • without support and/or a mutation predicting this form, e.g. PLP1 duplication
  • or higher copy numbers; known missense mutations associated with severe forms).

排除标准

  • - important comorbidity as another genetic disease
  • - liver or kidney disease
  • - neutropenia in patient's history
  • - severe iron deficiency

研究者

相似试验